Setting itself apart from the other players that only focus on the deciphering of DNA sequences for research purposes,
GC Genome is moving toward the goal of utilizing genomic information for disease diagnosis, disease screening and also precision medicine.
GC Genome leverages on the most up to date technologies including Next-Generation Sequencing (NGS) to provide distinguished services with shortened turnaround time, and affordable prices.
Moreover, we continue to invest heavily on R&D activities to develop services to fulfill the unmet needs of people and participate in the advancement of various global and national research projects.
Keep an eye out for GC Genome as we develop into a frontier company in genomic diagnostics and we will answer your support with our endless efforts and challenges.
Thank you.
History
2019
Launched GreenBiome Gut (Microbiome Test)10
Launched Distribution of Guardant 360 in Korea 07
2017
Selected as the Supervisory Institution for Korea-Czech Republic 11 Global R&D Cooperation project
Selected for Bio-industry Core R&D Project 10
Obtained KFDA Certification of Clinical NGS Laboratory04
Obtained CAP accreditation02
2015
Launched Pharmacogenetic Test 11
Selected as supervisory institution for Korea Post-Genome 08 Project
Obtained Level A (best accuracy) from the Korea Institute of 07Genetic Testing Evaluation
Launched G-NIPT (Non-invasive prenatal Test)04
2013
Genome Research Center approved by the Korean Government12
GC Genome Established08
07 Overall reorganization of website
05 Launched ‘Cancer Risk Screen plus Alcohol’ (Screening Test)
